Protalix Biotherapeutics, Inc. (PLX)
2.715
-0.02
(-0.55%)
USD |
NYAM |
Oct 07, 16:00
2.715
0.00 (0.00%)
After-Hours: 18:42
Protalix Biotherapeutics Gross Profit Margin (Quarterly) : 60.99% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 60.99% |
| March 31, 2026 | 87.77% |
| December 31, 2025 | 49.36% |
| September 30, 2025 | 53.37% |
| June 30, 2025 | 62.51% |
| March 31, 2025 | 19.11% |
| December 31, 2024 | 78.67% |
| September 30, 2024 | 53.37% |
| June 30, 2024 | 29.82% |
| March 31, 2024 | 30.58% |
| December 31, 2023 | 15.54% |
| September 30, 2023 | 52.70% |
| June 30, 2023 | 82.47% |
| March 31, 2023 | 67.82% |
| December 31, 2022 | 72.18% |
| September 30, 2022 | 50.12% |
| June 30, 2022 | 53.31% |
| March 31, 2022 | 62.49% |
| December 31, 2021 | 63.18% |
| September 30, 2021 | 69.28% |
| June 30, 2021 | 26.36% |
| March 31, 2021 | 57.91% |
| December 31, 2020 | 85.88% |
| September 30, 2020 | 73.42% |
| June 30, 2020 | 83.34% |
| Date | Value |
|---|---|
| March 31, 2020 | 84.17% |
| December 31, 2019 | 83.39% |
| September 30, 2019 | 77.51% |
| June 30, 2019 | 77.99% |
| March 31, 2019 | 80.41% |
| December 31, 2018 | 78.00% |
| September 30, 2018 | 84.46% |
| June 30, 2018 | 54.88% |
| March 31, 2018 | 35.78% |
| December 31, 2017 | 37.06% |
| September 30, 2017 | 19.40% |
| June 30, 2017 | 13.13% |
| March 31, 2017 | 27.73% |
| December 31, 2016 | 6.20% |
| September 30, 2016 | 9.04% |
| June 30, 2016 | 5.31% |
| March 31, 2016 | 22.98% |
| September 30, 2015 | 59.87% |
| June 30, 2015 | 55.83% |
| March 31, 2015 | 52.91% |
| December 31, 2014 | -13.95% |
| September 30, 2014 | 51.50% |
| June 30, 2014 | 40.25% |
| March 31, 2014 | 44.83% |
| December 31, 2013 | -38.32% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Altimmune, Inc. | -- |
| Taysha Gene Therapies, Inc. | -- |
| Humacyte, Inc. | -423.2% |
| Agenus, Inc. | 98.50% |
| Amgen, Inc. | 72.08% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 32.70% |
| Return on Assets | 20.78% |
| Return on Invested Capital | 28.77% |
| Profit Margin (Quarterly) | 18.98% |
| Operating Margin (Quarterly) | 23.48% |
| Return on Net Operating Assets | 38.68% |